REMS Need Metrics For Assessing Success, Burden On Health Care System
Executive Summary
“We don’t really have clear methods for assessing burden and access,” CDER’s Mary Willy acknowledges. A lack of baseline information hinders the measurement of whether REMS and their components are working.
You may also be interested in...
The Power Of The Public: Isotretinoin iPLEDGE Advisory Cmte. Is Case Study In An Effective OPH
Open public hearings can include both emotional patient testimony and angry, anti-industry proclamations. During the isotretinoin REMS panel, the OPH was particularly effective in making a case for easing patient access despite the risks. Will it get FDA on board?
Alexion’s Soliris REMS Gets FDA Panel Review In Wider Evaluation Effort
FDA advisory committee will revisit REMS for ultra-rare disease drug as part of larger agency effort to evaluate the effectiveness of the safety programs.
REMS Decision, Evaluation Guidances In Process, FDA Says
One draft guidance may be released this year outlining how FDA evaluates the risk-management programs.